



i PARTNERS

Kyna Global Equity Impact

Asset Class Equity

KYNA
Quantitative Investing


Basic figure

| | | | |
|----------------|----------------------------|---------------|---------------|
| Issuer | Opus - Chartered Iss. S.A. | Index Sponsor | i Partners SA |
| ISIN | DE000A4A5ZV2 | Currency | USD |
| NAV Date | 25.08.2025 | NAV (daily) | 1'016.24 |
| AUM | 6'200'000 | Components | 21 |
| Management Fee | 1.35% | TER | 1.57% |

Investment strategy

The certificate has been carefully crafted to seize opportunities in global equity markets while incorporating sustainable impact parameters provided by MSCI. Guided by Kyna, our proprietary algorithm, this certificate follows a meticulous approach to stock selection. With a commitment to sustainable and responsible investments, it offers investors privileged access to a diversified portfolio tailored for growth and sustainability. Through rigorous screening and in-depth analysis, we aim to deliver competitive returns while upholding the highest ethical and environmental standards. In doing so, we provide investors with a reliable and profitable avenue for capital growth, while maintaining a strong commitment to social and environmental responsibility.


Price chart



Performance

| | 2025 | 2024 | 2023 | 2022 |
|-----|-------|-------|-------|--------|
| Jan | 0.09 | -2.71 | 2.73 | -13.25 |
| Feb | 0.38 | 5.43 | -2.81 | 3.05 |
| Mar | -3.61 | 2.54 | 6.91 | 1.13 |
| Apr | 1.35 | -2.86 | -0.22 | -5.62 |
| May | 1.53 | 4.34 | 1.02 | -0.74 |
| Jun | 0.76 | -1.00 | 5.81 | -4.36 |
| Jul | 8.09 | 0.21 | 7.36 | 1.63 |
| Aug | 2.76 | 4.52 | -4.09 | -1.97 |
| Sep | | 1.46 | -0.86 | -7.22 |
| Oct | | -4.77 | -3.67 | 0.81 |
| Nov | | -2.63 | 10.57 | 9.06 |
| Dec | | -1.73 | 4.80 | -0.44 |
| YTD | 11.53 | 2.20 | 29.70 | -18.05 |

Sector Allocation %



Top 10 Holdings

| | |
|------------------------------|-------|
| ALNYLAM PHARMACEUTICALS INC | 9.64% |
| SINO BIOPHARMACEUTICAL | 7.00% |
| CSPC PHARMACEUTICAL GROUP LT | 6.74% |
| ACS ACTIVIDADES CONS Y SERV | 6.62% |
| KLEPIERRE | 6.60% |
| HANSOH PHARMACEUTICAL GROUP | 6.57% |
| KEPPEL LTD | 6.54% |
| INNOVENT BIOLOGICS INC | 6.51% |
| KINGDEE INTERNATIONAL SFTWR | 3.43% |
| COVIVIO | 3.30% |

Disclaimer

This document is for marketing purposes and it represents advertisement material and it is based on the prospectus. The content of this document has to be intended as a marketing communication issued by i Partners SA, Via Pretorio 9, 6900 Lugano (info@i-partners.ch). The present set of information are available only to professional investors resident in Switzerland within the meaning of art. 8(6), 68 FinSA, art. 95(1) FinSO. Its content is based upon information from deemed reliable sources, but it cannot be guaranteed as accurate, complete, valid or timely and it should not be relied on as such for any particular purpose. Any investment should be based solely on the prospectus, as well as the latest information available on the issuer webpage or on request. An investment in this product entails risks, which are fully described in the prospectus. Past performance is not a guide to future performance and may not be repeated. The value of an investment can rise or fall with market fluctuations and the originally invested amount be lost. Exchange rate changes may cause the value of any foreign investment to rise or fall.